 |
Nucleate PodcastAuthor: Nucleate
Nucleate is the new voice for next generation biotech leaders. Language: en Genres: Business, Entrepreneurship, Technology Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Functional Precision Oncology, a new compass for cancer care | Apricot Bio
Episode 39
Saturday, 20 December, 2025
In this special panel episode recorded in Zurich, the founders of Apricot Bio, Michael Zering (CEO), Lucas Pelkmans (Scientific Founder), and Independent Professor Andreas Wicki from the University of Zurich explore the new field of functional precision oncology—an approach that goes beyond genomics to test how living cancer cells actually respond to treatment. The conversation covers the limits of genetic diagnostics, the promise of ex vivo drug testing, AI-driven decision-making, and how smarter trial design could transform cancer care. The panel also dives into Switzerland’s biotech ecosystem, venture capital realities, and what it takes to bring high-risk, high-impact science from the lab to the clinic.00:00 – 03:30 | Introduction & Panel SetupRecorded in Zurich, this special panel episode introduces functional precision oncology and why current diagnostic paradigms are reaching their limits.03:30 – 12:00 | The Limits of Genomics in Cancer CareWhy genetic screening alone can’t capture tumor complexity, molecular heterogeneity, and real-world treatment response.12:00 – 22:00 | What Is Functional Precision Oncology?Testing patient-derived cancer cells ex vivo to understand drug response, cellular context, and therapeutic combinations.22:00 – 32:00 | “The Google Maps of the Cell” AnalogyHow contextual, real-time cellular data improves decision-making compared to static genetic snapshots.32:00 – 43:00 | Clinical Trials ReimaginedWhy traditional drug-centric trials struggle—and how diagnostic-led, patient-specific trials could change oncology research.43:00 – 53:00 | AI, Data Science & Cellular ContextHow machine learning models integrate phenotypic, spatial, and functional data to predict treatment response.53:00 – 1:03:00 | Drug Combinations & RepurposingWhy single agents often fail—and how functional testing uncovers synergistic therapies missed by standard screens.1:03:00 – 1:12:00 | Beyond Oncology: What Comes Next?Potential applications in immunology, hematology, neurology, and other diseases driven by cellular dysfunction.1:12:00 – 1:20:00 | Switzerland’s Biotech EcosystemStrengths, gaps, venture capital realities, and how Swiss innovation compares globally.1:20:00 – 1:23:00 | Founder Advice, Books & Closing ThoughtsLessons for scientist-founders, navigating tough funding environments, and recommended reading.
